ImmunityBio, Inc., a clinical-stage immunotherapy company, appointed Enrique Diloné, Ph.D., chief technology officer. With more than three decades of pharmaceutical manufacturing expertise, Diloné will assume responsibility for all global manufacturing functions as the company prepares for potential FDA approval of a key bladder cancer drug. He will report directly to president and CEO Richard Adcock. Diloné’s career spans more than 30 years of chemistry, manufacturing, and controls (CMC) man...